AN OPEN-LABEL SAFETY ASSESSMENT OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
- Registry ID
- 2015-01
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- REBIOTIX INC
- Start date
- 2016-07-25
- Last update
- 2015-08-27
Conditions
- CLOSTRIDIUM DIFFICILE INFECTION
Related clinical trials
- AN ADAPTIVE BASKET TRIAL TO EVALUATE EFFICACY OF LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION IN MANAGEMENT OF IRRITABLE BOWEL SYNDROME-DIARRHEA PREDOMINANT OR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
- AN EXPLORATORY, OPEN-LABEL, OLIGO-CENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS DNV3837 IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE INFECTION
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRS3123 COMPARED WITH ORAL VANCOMYCIN IN ADULTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION
- A PHASE 3 OPEN-LABEL CLINICAL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) IN SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
- A MULTI-CENTER, DOUBLE BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY OF LYOPHILIZED STERILE FECAL FILTRATE TO LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION (FMT) IN THE MANAGEMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
- A PHASE I, OPEN-LABEL, SINGLE-CENTRE STUDY OF THE SAFETY AND EFFICACY OF MET-2 IN PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (CDI)
View on source registry